Evidence map›Paper›PMID 38632318›Full record

ReviewActa pharmacologica Sinica2024

Frizzled receptors (FZDs) in Wnt signaling: potential therapeutic targets for human cancers.

Hui-Yu Liu, Xiao-Jiao Sun, Si-Yu Xiu, Xiang-Yu Zhang, Zhi-Qi Wang, Yan-Lun Gu, Chu-Xiao Yi, Jun-Yan Liu, Yu-Song Dai, Xia Yuan and 4 more

Open access · greenAbstract readReview
In one paragraph

Review in Acta pharmacologica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Oncology research · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Wnt/CaOncology letters · 2025
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Gen inhibiting the Wnt/CaScientific reports · 2025
    Article
  20. Anthraquinones fromDrug design, development and therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Hui-Yu Liu *Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing, 100034, China.
Xiao-Jiao Sun *State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Si-Yu XiuState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Xiang-Yu ZhangState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Zhi-Qi WangState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Yan-Lun GuDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Chu-Xiao YiState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Jun-Yan LiuDepartment of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing, 100034, China.
Yu-Song DaiDepartment of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing, 100034, China.
Xia YuanState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Hua-Peng LiaoYizhang County People's Hospital, Chenzhou, 424200, China.
Zhen-Ming LiuState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China. zmliu@bjmu.edu.cn.
Xiao-Cong PangDepartment of Pharmacy, Peking University First Hospital, Beijing, 100034, China. pangxiaocong1227@163.com.
Tian-Cheng LiDepartment of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing, 100034, China. litiancheng@bjmu.edu.cn.
Peking University · CNCapital Medical University · CNChenzhou First People's Hospital · CNChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frizzled receptors (FZDs) are key contributors intrinsic to the Wnt signaling pathway, activation of FZDs triggering the Wnt signaling cascade is frequently observed in human tumors and intimately associated with an aggressive carcinoma phenotype. It has been shown that the abnormal expression of FZD receptors contributes to the manifestation of malignant characteristics in human tumors such as enhanced cell proliferation, metastasis, chemotherapy resistance as well as the acquisition of cancer stemness. Given the essential roles of FZD receptors in the Wnt signaling in human tumors, this review aims to consolidate the prevailing knowledge on the specific status of FZD receptors (FZD1-10) and elucidate their respective functions in tumor progression. Furthermore, we delineate the structural basis for binding of FZD and its co-receptors to Wnt, and provide a better theoretical foundation for subsequent studies on related mechanisms. Finally, we describe the existing biological classes of small molecule-based FZD inhibitors in detail in the hope that they can provide useful assistance for design and development of novel drug candidates targeted FZDs.

Indexed as

Antineoplastic AgentsFrizzled ReceptorsNeoplasmsWnt Signaling PathwayAnimalsHumansMolecular Targeted TherapyAntineoplastic AgentsFrizzled Receptorscancer therapyFrizzled receptorsFZD inhibitorsstructural foundationWnt signaling pathway

Identifiers

PMID38632318
PMCPMC11272778
OpenAlexW4394883055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.